Solid Biosciences to Present at the Jefferies London Healthcare Conference
Solid Biosciences to Present at the Jefferies London Healthcare Conference
CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Combo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET).
2024年11月14日，马萨诸塞州查尔斯敦，Solid Biosciences Inc.（纳斯达克：SLDB）（"公司" 或 "Solid"），一家生命科学公司，致力于为神经肌肉和心脏疾病开发精准基因药物，今天宣布，总裁兼首席执行官Bo Combo和首席医疗官Gabriel Brooks.D.将于2024年11月20日星期三下午1:30，在格林威治标准时间（美国东部时间上午8:30）参加Jefferies伦敦医疗健康大会。
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.
演示的现场网络广播可以在公司网站的投资者部分的活动页面或点击此处进行观看。演示的网络重播将在活动页面上存档30天。
Institutional investors interested in meeting with management during the conference may reach out to their Jefferies representatives.
有意在会议期间与管理层会面的机构投资者可以联系杰弗里斯的代表。
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid's mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit .
关于固体生物科学（Solid Biosciences）
Solid Biosciences是一家专注于推进基因治疗候选品组合，包括SGt-003用于治疗肌营养不良(Duchenne)，SGt-501用于治疗儿茶酚胺能多形性室性心动过速（CPVT），Avb-401用于治疗BAG3介导性扩张性心肌病以及其他治疗致命心脏疾病的资产的精准基因药物公司。Solid正在推进其在罕见神经肌肉和心脏疾病的多样化管线，汇集了科学、技术、疾病管理和护理方面的专家。受患者关注和直接影响，Solid的宗旨是改善那些正在经历这些毁灭性疾病的患者的日常生活。请访问 了解更多信息。
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Solid Biosciences投资者联系方式：
Nicole Anderson
投资者关系和企业传播董事Nicole Anderson
solid biosciences 公司。
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
媒体联系：
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
Source: Solid Biosciences Inc.
来源：Solid Biosciences Inc.
热门市场机会
热门讨论
热门讨论
